Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.46 |
| ▸ | MTOR | P42345 | 7/20 | 0.45 |
| ▸ | TNKS | O95271 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533295 | 1.00 | MAP3K11 (0.46) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL481894 | 0.93 | MAP3K11 (0.47) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL481895 | 0.93 | MAP3K11 (0.47) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL481653 | 0.88 | MAP3K11 (0.49) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL481651 | 0.88 | MAP3K11 (0.49) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL2360980 | 0.87 | MAP3K11 (0.57) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL2533291 | 0.86 | MAP3K11 (0.46) | MAP3K11MTORTNKSPARP1PARP2 | |
| SCHEMBL2359028 | 0.84 | MTOR (0.59) | MAP3K11MTORJAK2JAK1JAK3 | |
| SCHEMBL481495 | 0.80 | MTOR (0.46) | MAP3K11MTORCNR2JAK2JAK1 | |
| SCHEMBL2504653 | 0.79 | MTOR (0.48) | MTORPIK3CAGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MAP3K11 44/4885MTOR 138/4885TNKS 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.